Shattuck Labs shares surge 10.77% intraday after HC Wainwright upgrades to 'Buy' with $6 target, citing SL-325's IBD therapy potential.

Shattuck Labs surged 10.77% in intraday trading, driven by HC Wainwright upgrading its rating to "buy" with a $6 price target, citing confidence in its lead candidate SL-325, a potential first-in-class DR3 antibody for inflammatory bowel disease. The company is advancing SL-325 into Phase 1 clinical trials, with the SAD portion initiated in Q3 2025 and completion of SAD/MAD enrollment expected by Q2 2026. Shattuck specializes in therapies for inflammatory and immune-mediated diseases.